Effectiveness and Safety of Intensive Triplet Chemotherapy Plus Bevacizumab, FIr-B/FOx, in Young-Elderly Metastatic Colorectal Cancer Patients

Table 4

Limiting toxicity syndromes (LTS): overall and in young-elderly patients.

	Overall		Young-elderly		Non-elderly
	No.	%	No.	%	No.	%
Patients	67	100	28	42	39	58
Limiting toxicity syndromes (LTS)	32	48	13	46	19	49
LTS single site (LTS-ss)	10	15	2	7	8	21
LTS multiple sites (LTS-ms)	22	33	11	39	11	28
Single LT plus G2-3	15	22	9	32	6	15
Double LTs	7	10	2	7	5	13

LT: limiting toxicity; G: grade.